Published: Mar 11, 2021
LONDON, March 11, 2021 (GLOBE NEWSWIRE) Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, announced today the appointment of Colin A. Love, PhD, to its Board of Directors with immediate effect. Dr. Love has over 30 years of experience leading biopharmaceutical company operations, including the development and launch of several biotechnology products.
“We are delighted to welcome Colin Love to Freeline’s Board of Directors,” said Theresa Heggie, Chief Executive Officer of Freeline. “His appointment comes at a key time as Freeline evolves into its next stage of growth, including the development, production and potential commercialization of the Company’s pipeline. Colin’s extensive experience in manufacturing complex biotechnology products will be valuable
Directorate Change Aston Martin Lagonda Global Holdings plc (the Company ) announces the following changes to the Board and its Committees to support the Company in its future ambitions. Anne Stevens, Robin Freestone, Richard Parry-Jones and Antony Sheriff are appointed to the Board as independent non-executive directors and Stephan Unger is appointed as the representative non-executive director of Mercedes-Benz AG, each appointment is effective 1 February 2021. Peter Espenhahn (Audit and Risk Committee Chair) and Lord Matthew Carrington (Remuneration Committee Chair) will support the Company through the publication of the 2020 financial results and will step down from the Board at the close of the AGM. Bill Tame will step down from the Board immediately.